Japan Experts, Extraordinary Performance, Astris Advisory Japan

Astris Advisory Japan

Japan Experts, Extraordinary Performance

Our Corporate Advisory service is designed to give clients access to a wider range of investors. These include Japan specialists as well as global investors. The goal is to help achieve a fair equity valuation.

Equity Bottom-Up

<ul><li>A soft start – Q1 FY6/26 results were relatively soft, with sales flat and OP still in negative territory.</li><li>This reflects the seasonally weak nature of Q1 and continued spending on R&amp;D.</li><li>The Optical segment remained strong, supported by resilient global demand, while the Life Science &amp; Equipment Development segment continued to progress, driven by consumables, maintenance services, and semiconductor equipment currently in the testing stage. </li></ul>

A soft start – Q1 FY6/26 results were relatively soft, with sales flat and OP still in negative territory.This reflects the seasonally weak nature of Q1 and continued spending on R&amp;D.The Optical segment remained strong, supported by resilient global demand, while the Life Science &amp; Equipment Development segment continued to progress, driven by consumables, maintenance services, and semiconductor equipment currently in the testing stage. 

JTEC Corp (3446 JP) - Strength in Optical Remains, Progress in Semiconductor

<ul><li>Momentum building – With a continued recovery at the core Optical segment, and high double-digit sales growth YoY at Life Science &amp; Equipment, we believe Q1-3 FY3/26 results indicate sustained upward momentum at JTEC.</li><li>The company has maintained FY6/25 guidance, and while this implies a back-end-loaded Q4 FY6/25, order visibility appears firm from demand on a global basis for the Optical business.</li><li>Indications of progress in the Life Science and Equipment Development segment, driven by the semiconductor initiative, are promising, even if its full earnings potential remains longer-term. </li></ul>

Momentum building – With a continued recovery at the core Optical segment, and high double-digit sales growth YoY at Life Science &amp; Equipment, we believe Q1-3 FY3/26 results indicate sustained upward momentum at JTEC.The company has maintained FY6/25 guidance, and while this implies a back-end-loaded Q4 FY6/25, order visibility appears firm from demand on a global basis for the Optical business.Indications of progress in the Life Science and Equipment Development segment, driven by the semiconductor initiative, are promising, even if its full earnings potential remains longer-term. 

JTEC Corp (3446 JP) -  Continued Uplift in Performance

<ul><li>Q1-2 FY6/25 results showed the core Optical business experienced sales growth and generated segmental profits, which was positive.</li><li>Focusing on developing the Life Science &amp; Equipment segment involving upfront investment resulted in flattish operating losses YoY overall.</li><li>FY company guidance has been maintained, implying an earnings recovery HoH driven by the Optical segment experiencing order visibility and new customer acquisition. </li></ul>

Q1-2 FY6/25 results showed the core Optical business experienced sales growth and generated segmental profits, which was positive.Focusing on developing the Life Science &amp; Equipment segment involving upfront investment resulted in flattish operating losses YoY overall.FY company guidance has been maintained, implying an earnings recovery HoH driven by the Optical segment experiencing order visibility and new customer acquisition. 

JTEC Corp (3446 JP) - Reaffirming Long-Term Vision

<ul>
<li>Improving sales mix lift gross margins – Gross margin increased to 65.9% in Q1 FY6/25 from 52.5% the previous year, demonstrating an improvement in the sales mix at the core Optical business segment which experienced demand for high-precision products with premium pricing.</li>
<li>While operating losses remained relatively flat YoY, the company is investing in IT systems that will improve its production and sales management which we believe will improve the quality of earnings, as well as assist in new business development.</li>
<li>Overall, we believe the company performed in line with guidance, with no change regarding expectations of the earnings profile to be concentrated in H2 FY6/25.</li>
</ul>


Improving sales mix lift gross margins – Gross margin increased to 65.9% in Q1 FY6/25 from 52.5% the previous year, demonstrating an improvement in the sales mix at the core Optical business segment which experienced demand for high-precision products with premium pricing.
While operating losses remained relatively flat YoY, the company is investing in IT systems that will improve its production and sales management which we believe will improve the quality of earnings, as well as assist in new business development.
Overall, we believe the company performed in line with guidance, with no change regarding expectations of the earnings profile to be concentrated in H2 FY6/25.


JTEC Corp (3446 JP) - Indications of Improving Returns

<ul><li>Q1-4 FY6/24 results were behind guidance, with the Optical business experiencing longer than expected customer inspection periods delaying revenue recognition.</li><li>The Life Science &amp; Equipment segment made some progress with new product sales, but positive earnings contributions are still further down the road in our view.</li><li>The company has lowered guidance for FY6/25 and FY6/26 as previously disclosed in the rolling three-year medium-term plan. </li></ul>

Q1-4 FY6/24 results were behind guidance, with the Optical business experiencing longer than expected customer inspection periods delaying revenue recognition.The Life Science &amp; Equipment segment made some progress with new product sales, but positive earnings contributions are still further down the road in our view.The company has lowered guidance for FY6/25 and FY6/26 as previously disclosed in the rolling three-year medium-term plan. 

JTEC Corp (3446 JP) - Maintaining Long-Term Growth Targets

Japan

JTEC Corporation of Osaka manufactures bio-technology systems and equipment. The Company produces life science devices, x ray mirrors, and automated cell culture systems. JTEC also develops pharmaceutical products. JTEC serves clients in Japan.

Price Gauge
52-week Range	0.00 - 0.00
Market Cap (USDm)	0.00
P/E	0.00
Dividend (Yield)	0.00

JTEC Corp/Osaka (3446 JP)

JTEC Corp (3446 JP) - Strength in Optical Remains, Progress in Semiconductor

A soft start – Q1 FY6/26 results were relatively soft, with sales flat and OP still in negative territory. This reflects the seasonally weak nature...

Astris Advisory Japan

JTEC Corp (3446 JP) - Continued Uplift in Performance

The company has maintained FY6/25 guidance, and while this implies a back-end-loaded Q4 FY6/25, order visibility appears firm from demand on a...

Astris Advisory Japan

JTEC Corp (3446 JP) - Reaffirming Long-Term Vision

Q1-2 FY6/25 results showed the core Optical business experienced sales growth and generated segmental profits, which was positive.

Astris Advisory Japan

JTEC Corp (3446 JP) - Indications of Improving Returns

Gross margin increased to 65.9% in Q1 FY6/25 from 52.5% the previous year, demonstrating an improvement in the sales mix at the core Optical...

Astris Advisory Japan

JTEC Corp (3446 JP) - Maintaining Long-Term Growth Targets

Q1-4 FY6/24 results were behind guidance, with the Optical business experiencing longer than expected customer inspection periods delaying revenue...

Astris Advisory Japan

Price Gauge

52-week Range

Market Cap (USDm)

P/E

Dividend (Yield)